Abstract
Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 pandemic, early signals of efficacy from convalescent plasma therapy have encouraged research and development of anti-SARS-CoV-2 mAbs. While many candidates are in preclinical development, we focus here on anti-SARS-CoV-2 neutralizing mAbs (or mAb cocktails) that represent the late-stage clinical pipeline, i.e., those currently in Phase 2 or Phase 3 clinical trials. We describe the structure, mechanism of action, and ongoing trials for VIR-7831, LY-CoV555, LY-CoV016, BGB-DXP593, REGN-COV2, and CT-P59. We speculate also on the next generation of these mAbs.
Keywords: BGB-DXP593; COVID-19; CT-P59; GSK4182136; LY-CoV016; LY-CoV555; REGN-COV2; SARS-CoV-2; VIR-7831; bamlanivimab; monoclonal antibody.
【저자키워드】 COVID-19, SARS-CoV-2, monoclonal antibody, bamlanivimab, REGN-CoV2, BGB-DXP593, CT-P59, GSK4182136, LY-CoV016, LY-CoV555, VIR-7831, 【초록키워드】 Efficacy, therapy, Pneumonia, antibody, Phase 2, COVID-19 pandemic, monoclonal antibody, clinical trials, research and development, anti-SARS-CoV-2, viral infections, bamlanivimab, Viral, Convalescent plasma therapy, respiratory syncytial virus, Research, Neutralizing, mechanism of action, disease, mechanism, mAbs, REGN-CoV2, LY-CoV555, mAb, phase, focus, virus pneumonia, candidate, ongoing trials, Ebolavirus, while, mAb cocktails, ongoing trial, 【제목키워드】 Neutralizing, monoclonal,